Cell-based delivery of oncolytic viruses: A new strategic alliance for a cancer

被引：86

作者：

Power, Anthony T. ^{[1
]}

Bell, John C. ^{[1
]}

机构：

[1] Univ Ottawa, Ctr Canc Therapeut, Ottawa Hlth Res Inst, Ottawa Hosp,Dept Biochem Microbiol & Immunol, Ottawa, ON K1H 1C4, Canada

来源：

MOLECULAR THERAPY | 2007年 / 15卷 / 04期

关键词：

D O I：

10.1038/sj.mt.6300098

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Recent years have seen tremendous advances in the development of exquisitely targeted replicating virotherapeutics that can safely destroy malignant cells. Despite this promise, clinical advancement of this powerful and unique approach has been hindered by vulnerability to host defenses and inefficient systemic delivery. However, it now appears that delivery of oncolytic viruses within carrier cells may offer one solution to this critical problem. In this review, we compare the advantages and limitations of the numerous cell lineages that have been investigated as delivery platforms for viral therapeutics, and discuss examples showing how combined cell-virus biotherapeutics can be used to achieve synergistic gains in antitumor activity. Finally, we highlight avenues for future preclinical research that might be taken in order to refine cell-virus biotherapeutics in preparation for human trials.

引用

页码：660 / 665

页数：6

共 66 条

[1] Expansion of cytolytic CD8+ natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon γ production [J].

Baker, J ;

Verneris, MR ;

Ito, M ;

Shizuru, JA ;

Negrin, RS .

BLOOD, 2001, 97 (10) :2923-2931

[2] Preferential targeting of vesicular stomatitis virus to breast cancer cells [J].

Bergman, I ;

Whitaker-Dowling, P ;

Gao, YH ;

Griffin, JA .

VIROLOGY, 2004, 330 (01) :24-33

[3] IL-2 adenovector-transduced autologous tumor cells reduce antitumor immune responses in patients with neuroblastoma [J].

Bowman, L ;

Grossmann, M ;

Rill, D ;

Brown, M ;

Zhong, WY ;

Alexander, B ;

Leimig, T ;

Coustan-Smith, E ;

Campana, D ;

Jenkins, J ;

Woods, D ;

Kitchingman, G ;

Vanin, E ;

Brenner, M .

BLOOD, 1998, 92 (06) :1941-1949

[4] Interleukin-2 gene-modified allogeneic tumor cells for treatment of relapsed neuroblastoma [J].

Bowman, LC ;

Grossmann, M ;

Rill, D ;

Brown, M ;

Zhong, WY ;

Alexander, B ;

Leimig, T ;

Coustan-Smith, E ;

Campana, D ;

Jenkins, J ;

Woods, D ;

Brenner, M .

HUMAN GENE THERAPY, 1998, 9 (09) :1303-1311

[5] An oncolytic measles virus engineered to enter cells through the CD20 antigen [J].

Bucheit, AD ;

Kumar, S ;

Grote, DM ;

Lin, YK ;

von Messling, V ;

Cattaneo, RB ;

Fielding, AK .

MOLECULAR THERAPY, 2003, 7 (01) :62-72

[6] Dissemination and growth of cancer cells in metastatic sites [J].

Chambers, AF ;

Groom, AC ;

MacDonald, IC .

NATURE REVIEWS CANCER, 2002, 2 (08) :563-572

[7] Pre-existent adenovirus antibody inhibits systemic toxicity and antitumor activity of CN706 in the nude mouse LNCaP xenograft model: Implications and proposals for human therapy [J].

Chen, Y ;

Yu, DC ;

Charlton, D ;

Henderson, DR .

HUMAN GENE THERAPY, 2000, 11 (11) :1553-1567

[8] Tumor-targeted, systemic delivery of therapeutic viral vectors using hitchhiking on antigen-specific T cells [J].

Cole, C ;

Qiao, J ;

Kottke, T ;

Diaz, RM ;

Ahmed, A ;

Sanchez-Perez, L ;

Brunn, G ;

Thompson, J ;

Chester, J ;

Vile, RG .

NATURE MEDICINE, 2005, 11 (10) :1073-1081

[9]

Coukos G, 1999, CLIN CANCER RES, V5, P1523

[10]

DePace N., 1912, Ginecologia, V9, P82

← 1 2 3 4 5 6 7 →